For decades, care for vision loss due to glaucoma has largely depended on detecting damage after it is in an advanced stage. In hereditary glaucoma, however, risk can often be identified years earlier, creating the possibility of intervention before major vision loss emerges. Pilot efforts in familial glaucoma increasingly suggest that earlier identification can alter care pathways when linked to sustained clinical follow-up.
The central challenge is no longer scientific feasibility alone, but whether such predictive systems can become clinically interpretable, operationally scalable and institutionally integrated within routine healthcare delivery.
When Prediction Changed Care
The practical implications of this shift are already visible in some familial glaucoma cases.
In one family from North 24-Parganas, West Bengal, multiple older members were already living with advanced vision loss from glaucoma, raising concerns that younger generations might face the same trajectory.
More than thirty family members underwent testing. Clinical and laboratory investigations revealed a well-characterised mutation in the Myocilin gene, a recognised cause of familial glaucoma. The pattern was strikingly consistent: every adult carrying the mutation had developed severe vision loss due to glaucoma, while teenagers and young adults were found to carry the same pathogenic variant despite having normal vision and few symptoms, implying that they too will meet the same fate.
Under conventional practice, most would likely have entered the healthcare system only after significant damage had already occurred. Instead, high-risk family members carrying the mutation entered structured monitoring programmes. Raising eye pressure was detected early, clinical observation became more frequent and intervention decisions were made before visible deterioration occurred.
Nearly two years later, these younger family members have controlled eye pressure, no progressive vision loss and freedom from long-term medication.
The experience of this family also exposes a broader question. Can such intervention remain confined to isolated cases, or can it become clinically and operationally scalable?
Demonstrating Technical Viability
Scientific progress has moved rapidly since the first glaucoma-associated genes were identified nearly three decades ago. A customised glaucoma panel launched in late 2025 illustrates this transition from research toward applied clinical use.
The panel sequences 21 genes known to be causally associated with glaucoma. Initial retrospective validation across 48 previously characterised samples from multiple Indian clinical centres correctly identified the known pathogenic mutation in every case.
Following retrospective validation, a further 48 prospective patient samples were sequenced in carefully selected familial and early-onset glaucoma cases. Tests identified causal mutations in around one-fifth of patients, aligning with the upper range of current international expectations for such cohorts.
These findings suggest that predictive testing is increasingly moving beyond proof-of-concept research and toward practical clinical application.
Why Technology Alone Was Insufficient
The experience of implementing predictive care demonstrated that early identification depended on several connected forms of support often treated separately in healthcare delivery: diagnostics, counselling, longitudinal monitoring, transport support and clinician coordination.
Genetic counselling proved especially important because predictive information can be probabilistic, emotionally complex and often family-wide in implication. Most ophthalmologists operating under heavy outpatient pressures cannot realistically be expected to interpret multigenerational pedigrees, explain recurrence risks and guide long-term preventive decisions. Counsellors therefore become a critical bridge between molecular findings and actionable care.
Continuity support systems proved equally important. Regular monitoring required repeated hospital visits despite precarious economic conditions. The Rotary Club of Kolkata (Jadavpur) helped offset travel and opportunity costs, allowing sustained follow-up that would otherwise have been difficult to maintain. Such support may appear peripheral to medical policy, but in practice it often determines whether preventive care remains feasible for vulnerable households.
Industry partnerships also matter in this context, not simply as suppliers of laboratory tests but as contributors to diagnostic infrastructure. Standardised partnerships can improve affordability, consistency and turnaround time across care systems. International experiences, including the United Kingdom’s 100,000 Genomes Project, demonstrate how genomics can be linked to routine care pathways through institutional coordination.
India today already possesses much of the scientific foundation required for predictive care: clinical expertise, biotechnology capacity and rapidly improving sequencing technologies. The more difficult task lies in connecting these capabilities into functioning preventive pathways.
Building Public Pathways for Predictive Care
The lessons emerging from familial glaucoma point toward a broader prevention-first approach to hereditary disease.
Targeted genetic testing for suspected inherited glaucoma can be incorporated into structured clinical pathways that include counselling, regular monitoring and timely intervention. Many delivery mechanisms already exist within India’s expanding preventive and community-health infrastructure.
Several areas now warrant attention: regional DNA isolation and sample-handling facilities, regulated pathways for moving samples between peripheral clinics and central laboratories, subsidised transport support for vulnerable families and integrated counselling services within ophthalmology systems.
Community-level awareness programmes and school-based vision initiatives may also help identify hereditary clusters earlier, particularly in families where blindness has historically been normalised across generations. Familial paediatric and juvenile primary open-angle glaucoma should therefore be considered more explicitly within programmes such as Rashtriya Bal Swasthya Karyakram and linked to broader rare-disease and preventive-health strategies.
Genetics as Time
Prevention over management in glaucoma is increasingly achievable where earlier identification, clinical judgement, counselling and continuity of care operate together. The implications extend beyond glaucoma toward a broader transition in how hereditary conditions may be approached.
Genetics offers more than prediction; it offers time – to intervene, to prepare and to preserve vision. Translating that time into better outcomes will require healthcare systems, clinicians, policymakers, counsellors, industry partners and philanthropic institutions to build the preventive pathways that make anticipatory care routine rather than exceptional.